In a report released yesterday, Gianluca Tucci from Haywood maintained a Buy rating on HEALWELL AI, with a price target of C$4.50.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gianluca Tucci has given his Buy rating due to a combination of factors tied to HEALWELL AI’s strengthening operating engine and emerging monetization opportunities. He notes that integration work is largely finished, commercial collaboration with Orion is progressing from planning to real sales activity, and the roadmap includes near‑term triggers such as the upcoming Amadeus AI launch, while a sizable stake in xAI (now within SpaceX) offers potential non‑dilutive funding.
He also highlights that consolidating Khure and Pentavere into the DARWIN engine, and embedding targeted AI tools into Orion’s and Verosource’s platforms, opens a scalable cross‑sell channel into Orion’s worldwide client base, supporting meaningful revenue growth from 2026 onward. The planned North American introduction of Amadeus AI in the first half of 2026, followed by international rollout, is seen as a key proof point for platform stickiness and long‑term SaaS/AI value creation, underpinning his positive stance on the shares.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a C$2.50 price target.